Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 5,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infection Clear all

Conditions: Rotavirus Infections
Interventions: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo; Biological · Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cesarean Section, Wound Complications, Patient Satisfaction, Pain Measurement
Interventions: Staples, Suture; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Female only
Enrollment: 746 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: New Haven, Connecticut • Philadelphia, Pennsylvania

Conditions: Congenital Cytomegaloviral (CMV) Disease
Interventions: CMV Cytotoxic T-Lymphocytes, Anti-viral Therapy; Biological · Drug
Lead sponsor: New York Medical College; Other
Eligibility: 0 Days to 21 Days
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • St Louis, Missouri • Vallhala, New York + 1 more

Conditions: Necrotizing Enterocolitis, Intra-abdominal Infection
Interventions: meropenem; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: Up to 90 Days
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Oakland, California • Orange, California + 21 more

Conditions: Anti-biotic Resistance
Interventions: VSL#3, sugar pill (placebo); Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Chronic Genotype 1 Hepatitis C Virus Infection
Interventions: PPI-461, Placebo; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Sacramento, California • San Francisco, California

Conditions: Catheter-Associated Urinary Tract Infection
Interventions: ReadyCleanse Cloths; Device
Lead sponsor: Medline Industries; Industry
Eligibility: 18 Years and older
Enrollment: 9,891 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Evanston, Illinois • Glenview, Illinois • Highland Park, Illinois + 1 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Interventions: Lopinavir / ritonavir; Drug
Lead sponsor: Daré Bioscience, Inc.; Industry
Eligibility: 22 Years to 50 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 7 more

Conditions: Non-Healing Ulcer of Skin, Autofluorescence Imaging
Interventions: MolecuLight; Device
Lead sponsor: Wound Care Plus, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Blue Springs, Missouri

Conditions: Anemic, Critically Ill Patients
Interventions: Ferrous Sulfate, Placebo Oral Tablet; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Methicillin-Resistant Staphylococcus Aureus, Cystic Fibrosis
Interventions: Intervention N/A. Observational study; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 4 Years to 99 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina • Seattle, Washington

Conditions: COVID-19 Pneumonia, COVID-19
Interventions: Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine; Biological
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Timeline: 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infection
Interventions: Griffithsin Gel, Placebo Gel; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Diego, California • Dallas, Texas

Conditions: Herpes Genitalis
Interventions: VCL-HB01, Phosphate-buffered saline; Biological · Other
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more

Conditions: Cough
Interventions: CRP point of care testing; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Fecal Microbiota Transplantation; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment
Interventions: peri-implantitis surgery with enamel matrix derivative; Procedure
Lead sponsor: North Dallas Dental Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections, Central Nervous System Diseases
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions: Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration; Drug · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Clostridium Difficile Infection
Interventions: Alanyl-glutamine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Bloodstream Infection
Interventions: 70% ethanol, heparin flush solution; Drug
Lead sponsor: Baystate Medical Center; Other
Eligibility: 6 Months to 23 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS)
Interventions: Romiplostim; Drug
Lead sponsor: Anjali Sharathkumar; Other
Eligibility: 0 Years to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

Cesarean Trial of Staples vs. Sutures

CMV CTLs in Neonates With CMV Infection

Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections

A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Efficacy of a Prepackaged Cleansing Cloth and Standardized Cleansing Protocol for Catheter Care at Reducing CAUTI Rates

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

Retrospective Database Review at LTC and SNFs

Efficacy of Enteral Iron Supplementation in Critical Illness

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

C-reactive Protein (CRP)-Guided Management Algorithm for Adults With Acute Cough

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)

Central Nervous System Disease in HIV-infected Children on HAART

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

Ethanol Locks for the Treatment of Central Venous Line Infections

TPO-Mimetic Use in Children for Hematopoietic Failure